Associations of preoperative stroke and tranexamic acid administration with convulsive seizures in valvular open-heart surgery

In cardiac surgery, the antifibrinolytic agent tranexamic acid (TXA) has been associated with convulsive seizures [1]. The underlying pharmacologic mechanism is considered to be a disinhibition of cerebral glycine and gamma-aminobutyric acid receptors [2]. To date, increasing TXA dose and open-heart surgery are the only parameters that have been clearly established as underlying risk factors of convulsive seizures [1‐3]. In the large randomized, placebo-controlled ATACAS (Aspirin and Tranexamic Acid for Coronary Artery Surgery) trial that included patients undergoing isolated valvular or combined valvular and coronary artery bypass grafting (CABG) surgery, use of TXA (100 mg and 50 mg per kg body weight in 75% and 25% of trial participants, respectively) was associated with a higher risk of postoperative seizures than in the placebo group [3]. In addition, a strong positive relationship between a perioperative stroke and a seizure was observed [3]. We therefore hypothesized that a history of stroke may also be a critical risk factor for TXA-associated seizures. To test this hypothesis, we analyzed data from our high-volume center over the last 10 years.

Use of TXA and a history of stroke were both independently associated with convulsive seizure (Supplemental Table 1). The four groups of patients with or without preoperative stroke and with or without perioperative TXA administration differed substantially with respect to most baseline characteristics assessed, with the exception of age and smoking status (Table 1). Compared to patients without TXA administration, the adjusted OR of experiencing a seizure in TXA patients without a history of stroke was 2.44 (95%CI: 1.71–3.46) and in patients receiving TXA with a history of stroke 4.30 (95%CI: 2.65–6.99) (Table 2). There was, however, no significant interaction between TXA use and preoperative stroke on convulsive seizures (P = 0.77).

In-hospital mortality and 30-day mortality were 3.4% (n = 547) and 3.5% (n = 569), respectively. Compared with patients without seizure, for patients with seizure, inverse probability-weighted in-hospital mortality and 30-day mortality were 3.58 (95%CI: 2.20–5.83) and 4.04 (95%CI: 2.34–6.98), respectively.

Our results indicate that a history of stroke and use of TXA are both independently associated with an increased risk of seizure in patients undergoing valvular open-heart surgery. However, our data do not support the hypothesis of a significant interaction of both parameters on the risk of seizure.

It is well known that, in open-heart surgery, TXA dose-dependently increases the risk of convulsive seizure [1, 3]. This is attributed to toxic TXA concentrations (≥ 200 µM) in the cerebral fluid. The underlying cause is considered to be an increased permeability of the blood–brain barrier due to systemic inflammation and its jeopardization via micro-air embolism following open-heart surgery or cerebral injury [2]. With respect to acute stroke, dysfunction of the blood–brain barrier is a prominent characteristic, and it is unclear whether complete restoration occurs [4]. Therefore, a history of stroke may increase the risk of seizure by persistent blood–brain barrier impairment, particularly in the aged brain [4]. However, the concept of an impaired blood–brain barrier has been challenged by the results of two recent large randomized placebo-controlled trials in acute traumatic brain injury and acute intracerebral hemorrhage [5, 6]. In both trials, the dosing of TXA was almost comparable to our protocol. The CRASH-3 (Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage) trial allocated 12,737 patients with traumatic brain injury to TXA or matching placebo [5]. The risk of developing seizures did not differ significantly between groups [5]. The TICH-2 (Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage) trial allocated 2325 patients with acute spontaneous intracerebral hemorrhage to TXA or matching placebo [6]. The incidence of seizures in both groups was 7% [6]. These data show that the mechanisms leading to toxic TXA concentrations in cardiac surgery and potentially promoting stroke-related convulsive seizures require further research. The results of the two aforementioned studies are also in line with our finding that there was no significant interaction between a history of stroke and TXA administration on seizures. Obviously, there is no similar mechanism of how both parameters may influence the risk of seizures.

It should be emphasized that our results of a higher short-term mortality risk in patients with seizures than in patients without seizures are in line with earlier findings [3].

Our investigation has several limitations that have to be addressed. First, the retrospective study design prevents us from assuming causal relationships between risk factors and outcomes. Second, the small numbers of patients in the two groups with a history of stroke may have reduced statistical power for detecting significant interactions between use of TXA and a history of stroke on convulsive seizures. Third, we cannot rule out that study results are biased by unexplained confounding. Finally, the propensity score for calculating inverse probability weighting was solely based on preoperative covariate data and did not include perioperative parameters.

In summary, our data indicate that, in patients undergoing open-heart surgery, a history of stroke is independently associated with convulsive seizures. Since there was no significant interaction between TXA use and preoperative stroke on convulsive seizures, a history of stroke is not a contraindication for TXA use.